Skip to main content

Table 2 Association between MX treatment and the occurrence of symptomatic congestive heart failure

From: Cardiovascular comorbidity in multiple sclerosis patients treated with Mitoxantrone therapy: a cohort study

Variable

RR (CI)a

p

Age

3.57 (0.98 – 19.9)

0.12

Gender

1.05 (0.70 – 2.40)

1

Disease duration

0.8 (0.7 – 1.1)

0.3

Cumulative dose

2.3 (1.54 – 3.66)

0.000003

Number of infusion

2.3 (1.4 – 3.8)

0.0003

  1. aRR = relative risk. CI = 95% confidence intervals